1. High throughput screening aids clinical decision-making in refractory acute myeloid leukaemia.
- Author
-
Jessop SJ, Fuentos-Bolanos N, Mayoh C, Dolman MEM, Tax G, Wong-Erasmus M, Ajuyah P, Tyrell V, Marshall GM, Ziegler DS, and Lau LMS
- Subjects
- Humans, Pyrazoles therapeutic use, Nitriles therapeutic use, Pyrimidines therapeutic use, Male, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Hydroxyurea therapeutic use, Hydroxyurea administration & dosage, Middle Aged, Oncogene Proteins, Fusion genetics, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute therapy, Clinical Decision-Making methods, High-Throughput Screening Assays methods
- Abstract
Background: Despite advances in therapeutics for adverse-risk acute myeloid leukaemia (AML), overall survival remains poor, especially in refractory disease. Comprehensive tumour profiling and pre-clinical drug testing can identify effective personalised therapies., Case: We describe a case of ETV6-MECOM fusion-positive refractory AML, where molecular analysis and in vitro high throughput drug screening identified a tolerable, novel targeted therapy and provided rationale for avoiding what could have been a toxic treatment regimen. Ruxolitinib combined with hydroxyurea led to disease control and enhanced quality-of-life in a patient unsuitable for intensified chemotherapy or allogeneic stem cell transplantation., Conclusion: This case report demonstrates the feasibility and role of combination pre-clinical high throughput screening to aid decision making in high-risk leukaemia. It also demonstrates the role a JAK1/2 inhibitor can have in the palliative setting in select patients with AML., (© 2024 The Authors. Cancer Reports published by Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF